|
Celgene Corp.
Ticker Symbol: CELG* CUSIP: 151020104 Exchange: NGS
* NOTE: This security is no longer trading as of 11/20/2019
Company's Online Profile
BUSINESS: Celgene Corp. is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.
|
Find All Related Securities for CELG*
Notes: NOVEMBER 20, 2019 Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by Bristol-Myers Squibb and Celgene stockholders. Upon completion of the acquisition, pursuant to the terms of the merger agreement, Celgene became a wholly owned subsidiary of Bristol-Myers Squibb Company. Under the terms of the merger, Celgene shareholders received for each share, 1.00 share of Bristol-Myers Squibb common stock, $50.00 in cash without interest and one tradeable Contingent Value Right (CVR), which will entitle the holder to receive a payment of $9.00 in cash if certain future regulatory milestones are achieved. Celgene common stock ceased trading as of the close of trading today. On November 21, 2019, newly issued Bristol-Myers Squibb shares and CVRs will commence trading on the New York Stock Exchange, with the CVRs trading under the symbol “BMYRT.” Celgene Corporation (NASDAQ: CELG) announced that following the completion of Celgene’s acquisition by Bristol-Myers Squibb Company (NYSE: BMY), Bristol-Myers Squibb and Celgene plan to transfer the listing of Celgene’s contingent value rights (NASDAQ: CELGZ) (“Celgene CVRs”) that are related to Celgene’s ABRAXANE® product from the NASDAQ Global Market to the New York Stock Exchange (“NYSE”). As a result, Celgene notified the NASDAQ Global Market today of its intent to initiate the voluntary delisting of the Celgene CVRs. The Celgene CVRs are expected to begin trading on the NYSE under the symbol “CELGRT” following their official delisting from the NASDAQ Global Market, which is expected to occur on December 2, 2019.
|
Large Cap Stock -
Market Value $70.6 Billion
|
Company's Online Information Links
|
| Company's Online SEC EDGAR Filings |
| Company's Email Address Links |
| Address and Phone Numbers |
| Address: 86 Morris Avenue, Summit, NJ 07901 |
| Main Phone Number |
908-673-9000 |
| Fax Number |
908-673-9001 |
| Investor Relations
|
908-673-9969
|
Toll Free Phone Number |
Unknown |
| CEO - Mark J. Alles |
CFO - Peter N. Kellogg |
Find a problem? Please use our Feedback Page or Email us.
Have you filled out our Guestbook? If not, please do.
|
|
